Braf and erbB2 mutations correlate with smoking status in lung cancer patients

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 771-775

  Sasaki, Hidefumi ^a   Shitara, Masayuki ^a   Yokota, Keisuke ^a   Okuda, Katsuhiro ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Adenocarcinoma; Braf; Epidermal growth factor receptor; erbB2; Lung cancer; Mutations

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CIGARETTE SMOKING; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WILD TYPE;

EID: 84858666195     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.500     Document Type: Article

References (32)

1. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
2. Rowinsky EK: The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55: 433-457, 2004.
3. Wieduwilt MJ and Moasser MM: The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65: 1566-1584, 2008.
4. Laurent-Puig P, Lievre A and Blons H: Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 15: 1133-1139, 2009.
5. Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62, 2001.
6. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
7. Brose MS, Voipe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000, 2002.
8. Naoki K, Chen T-H, Richards WG, Sugarbaker DJ and Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003, 2002.
9. Hoque MO, Brait M, Rosenbaum E, et al: Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J Thorac Oncol 5: 1887-1893, 2010.
10. Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas harboring Braf mutations. J Clin Oncol 29: 2046-2051, 2011.
11. Lee YS, Kim MJ, Jin G, et al: Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 5: 1734-1740, 2010.
12. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
13. Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006.
14. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Eng J Med 350: 2129-2139, 2004.
15. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
16. Sasaki H, Endo H, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005.
17. Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Eng J Med 361: 947-957, 2009.
18. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer habouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-128, 2010.
19. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Eng J Med 362: 2380-2388, 2010.
20. Stephens P, Hunter C, Bignell G, et al: Intragenic erbB2 kinase mutations in tumors. Nature 431: 525-526, 2004.
21. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646, 2005.
22. Tomizawa K, Suda K, Onozato R, et al: Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74: 139-144, 2011.
23. Sasaki H, Kawano O, Endo K, et al: Uncommon V599E Braf mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206, 2006.
24. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol 6: 15-20, 2011.
25. Ikenoue T, Hikiba Y, Kanai F, et al: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63: 8132-8137, 2003.
26. Ji H, Wang Z, Perera SA, et al: Mutations in Braf and Kras converse on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939, 2007.
27. Welbrock C and Huristone A: BRAF as therapeutic target in melanoma. Biochem Pharmacol 80: 561-567, 2010.
28. Solit DR, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362, 2006.
29. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated activated Braf in metastatic melanoma. N Eng J Med 363: 809-819, 2010.
30. Minami Y, Shimamura T, Shah K, et al: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26: 5023-5027, 2007.
31. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e213, 2005.
32. Sasaki H, Endo K, Takada M, et al: EGFR exon20 insertion mutation in Japanese lung cancer. Lung Cancer 58: 324-328, 2007.